← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 607개
AntibodyRocheVedotin-Based Polatuzumab V…Phase 2

rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 76%임상시험 32상태 RECRUITING
ADCBiologicstaleNanogen Pharmaceutical Biotechn…Phase 2

Neulasta (Neulasta)

Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 7%임상시험 31상태 ACTIVE
ADCBiologicstaleCzech Lymphoma Study GroupPhase 2

Prednisone tablet (Prednisone tablet)

Lymphoma, T-Cell, Peripheral · Lymphoma, T-Cell, Peripheral

#LymphomaT-CellPeripheral#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 16.8%임상시험 31상태 ACTIVE
ADCBiologicstalePharmacyclics LLC.Phase 3

Procarbazine Hydrochloride (Procarbazine Hydrochloride)

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 · Lugano Classification Limited Stage Hodg

#LuganoClassificationLimitedStage#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 1%임상시험 31상태 RECRUITING
AntibodystaleRochePreclinical

Mabthera®, Roche Pty Ltd, Basel, Switzerland (Rituximab, Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland))

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#Antibody#Preclinical#항체#면역항체+2
효능 ORR 4%임상시험 31상태 ACTIVE
AntibodyBiologicstaleSeagen Inc.Phase 2

anti-CD30 mAb (SGN-30, SGN-30 (anti-CD30 mAb))

Anaplastic Large-Cell Lymphoma · CD30

#CD30#Antibody#Phase2#항체#면역항체+3
효능 ORR 89.5%임상시험 31상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 2

SGN-35 (SGN-35)

Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic · Disease, Hodgkin

#DiseaseHodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 89.5%임상시험 31상태 ACTIVE
CGTBiologicstaleWuhan Sian Medical Technology C…Phase 2

Second generation CAR-T cells (Second generation CAR-T cells)

Acute Lymphoblastic Leukemia; B Cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 31상태 ACTIVE
ADCBiologicstaleTakedaPhase 1

TAK228 (TAK228)

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Classical Hodgkin Lymphoma · CD30

#CD30#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 18.4%임상시험 31상태 DISCONTINUED
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 69.3%임상시험 31상태 RECRUITING
ADCBiologicstaleMylan Pharmaceuticals IncPhase 1

Verapamil (Verapamil)

Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 31상태 ACTIVE
ADCBiologicstaleSWOG Cancer Research NetworkPhase 2

Velban (Vinblastine, Vinblastine (Velban))

Anaplastic Large Cell Lymphoma, ALK-Positive · Anaplastic Large Cell Lymphoma, ALK-Posi

#AnaplasticLargeCellLymphomaALK-P#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 96%임상시험 31상태 RECRUITING
AntibodyRocheVedotin Plus an Anti-CD20 M…Phase 2

Zanubrutinib and Rituximab (Zanubrutinib and Rituximab)

Untreated Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 48.7%임상시험 31상태 RECRUITING
CGTBiologicstaleRui Therapeutics Co., LtdPhase 1

anti-CD19 CAR-NK cells (anti-CD19 CAR-NK cells)

Refractory/Recurrent Central Nervous System Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 0%임상시험 31상태 ACTIVE
AntibodystaleBiogenPhase 2

90-Y-ibritumomab tiuxetan (90-Y-ibritumomab tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 89%임상시험 30상태 ACTIVE
AntibodyRochevedotin and anti-CD19 chime…Phase 2

Acalabrutinib combination with Rituximab (Acalabrutinib combination with Rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.4%임상시험 30상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 2

Adriamycin, vinblastine, and dacarbazine (Adriamycin, vinblastine, and dacarbazine)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 96%임상시험 30상태 ACTIVE
CGTBiologicInstituto de Investigación Hosp…Phase 1

Autologous CD19/CD22 CAR T cells (Autologous CD19/CD22 CAR T cells)

Precursor Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 30상태 RECRUITING
AntibodystaleRochePhase 2

Bendamustine + Rituximab (Bendamustine + Rituximab)

Marginal Zone Lymphoma(MZL) · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 RECRUITING
CGTBiologicstaleMinsk Scientific-Practical Cent…Phase 2

CD19+22 CAR-T cells (CD19+22 CAR-T cells)

Acute Lymphobkastic Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 1%임상시험 30상태 RECRUITING

6 / 31 페이지

← 이전다음 →